In this Issue:
Radium-223 and docetaxel in castration-resistant prostate cancer
OS with chemohormonal vs hormonal therapy for metastatic prostate cancer
Physician variation in management of low-risk prostate cancer
Multiparametric MRI outperforms Prostate Cancer Prevention Trial risk calculator
Secondary endpoints in the AFFIRM trial
Enzalutamide vs docetaxel post abiraterone
17-gene assay to predict prostate cancer aggressiveness
Spinal fractures after androgen suppression and zoledronic acid
High-dose IMRT vs combined brachytherapy plus IMRT for prostate cancer
Please login below to download this issue (PDF)